Skip to main content
SpringerLink
Log in

Complementary and Integrative Therapies for Older Age Bipolar Disorder

  • Chapter
  • First Online:
Book cover Bipolar Disorder in Older Age Patients

  • 1086 Accesses

Abstract

There is a growing interest in complementary and alternative medicine (CAM) in psychiatric disorders, including bipolar disorder. Individuals may continue to experience symptoms and impairment from their illness despite appropriate pharmacologic treatment. Moreover, psychotropic medications can be especially problematic for many older adults with regard to adverse effects, tolerability, and drug interactions. Complementary and alternative therapies may fill the gaps where traditional treatment modalities fall short. Treatment goals may range from alleviating residual symptoms to improving quality of life and general well-being. There is a dearth of research on CAM in older age bipolar disorder but there is growing research in adult psychiatric populations more generally. CAM studies often have methodological limitations, and so findings should be interpreted with caution. This chapter aims to give a general overview of CAM therapies to consider as adjuncts to standard treatment, including several nutraceutical supplements and meditation. CAM offers the opportunity to take a truly integrative approach to psychiatric care. Psychiatrists have the ability not only to treat troubling symptoms, but also to improve patients’ quality of life. Incorporating dietary supplements when indicated, promoting exercise and nutrient rich diets, and teaching mindfulness and acceptance can be key ingredients in achieving wellness for bipolar patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. National Center for Complementary and Integrative Health Bethesda 2008 [updated Mar 2015]. Available from: https://nccih.nih.gov/health/integrative-health-cvsa.

  2. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Rep. 2008;12:1–23.

    Google Scholar 

  3. Schnabel K, Binting S, Witt CM, Teut M. Use of complementary and alternative medicine by older adults—a cross-sectional survey. BMC Geriatr. 2014;14:38.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Astin JA, Pelletier KR, Marie A, Haskell WL. Complementary and alternative medicine use among elderly persons: one-year analysis of a Blue Shield Medicare supplement. J Gerontol Ser A Biol Sci Med Sci. 2000;55(1):M4–9.

    Article  CAS  Google Scholar 

  5. Cheung CK, Wyman JF, Halcon LL. Use of complementary and alternative therapies in community-dwelling older adults. J Altern Complement Med (New York, NY). 2007;13(9):997–1006.

    Google Scholar 

  6. Cohen RJ, Ek K, Pan CX. Complementary and alternative medicine (CAM) use by older adults: a comparison of self-report and physician chart documentation. J Gerontol Ser A Biol Sci Med Sci. 2002;57(4):M223–7.

    Article  Google Scholar 

  7. Najm W, Reinsch S, Hoehler F, Tobis J. Use of complementary and alternative medicine among the ethnic elderly. Altern Ther Health Med. 2003;9(3):50–7.

    PubMed  Google Scholar 

  8. Williamson AT, Fletcher PC, Dawson KA. Complementary and alternative medicine. Use in an older population. J Gerontol Nurs. 2003;29(5):20–8.

    Article  PubMed  Google Scholar 

  9. Grzywacz JG, Suerken CK, Quandt SA, Bell RA, Lang W, Arcury TA. Older adults’ use of complementary and alternative medicine for mental health: findings from the 2002 National Health Interview Survey. J Altern Complement Med (New York, NY). 2006;12(5):467–73.

    Google Scholar 

  10. Keaton D, Lamkin N, Cassidy KA, Meyer WJ, Ignacio RV, Aulakh L, et al. Utilization of herbal and nutritional compounds among older adults with bipolar disorder and with major depression. Int J Geriatr Psychiatry. 2009;24(10):1087–93.

    Article  PubMed  Google Scholar 

  11. Jarman CN, Perron BE, Kilbourne AM, Teh CF. Perceived treatment effectiveness, medication compliance, and complementary and alternative medicine use among veterans with bipolar disorder. J Altern Complement Med (New York, NY). 2010;16(3):251–5.

    Google Scholar 

  12. Ravindran AV, da Silva TL. Complementary and alternative therapies as add-on to pharmacotherapy for mood and anxiety disorders: a systematic review. J Affect Disord. 2013;150(3):707–19.

    Article  PubMed  Google Scholar 

  13. van der Watt G, Laugharne J, Janca A. Complementary and alternative medicine in the treatment of anxiety and depression. Curr Opin Psychiatry. 2008;21(1):37–42.

    Article  PubMed  Google Scholar 

  14. Andreescu C, Mulsant BH, Emanuel JE. Complementary and alternative medicine in the treatment of bipolar disorder–a review of the evidence. J Affect Disord. 2008;110(1–2):16–26.

    Article  PubMed  Google Scholar 

  15. Sarris J, Mischoulon D, Schweitzer I. Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder: a systematic review of clinical trials. Bipolar Disord. 2011;13(5–6):454–65.

    Article  CAS  PubMed  Google Scholar 

  16. Sarris J, Lake J, Hoenders R. Bipolar disorder and complementary medicine: current evidence, safety issues, and clinical considerations. J Altern Complement Med (New York, NY). 2011;17(10):881–90.

    Google Scholar 

  17. Fleck DE, Keck PE Jr, Corey KB, Strakowski SM. Factors associated with medication adherence in African American and white patients with bipolar disorder. J Clin Psychiatry. 2005;66(5):646–52.

    Article  PubMed  Google Scholar 

  18. Miklowitz DJ, Johnson SL. The psychopathology and treatment of bipolar disorder. Annu Rev Clin Psychol. 2006;2:199–235.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Bourre JM. Effects of nutrients (in food) on the structure and function of the nervous system: update on dietary requirements for brain. Part 1: micronutrients. J Nutr Health Aging. 2006;10(5):377–85.

    CAS  PubMed  Google Scholar 

  20. Kaplan BJ, Crawford SG, Field CJ, Simpson JS. Vitamins, minerals, and mood. Psychol Bull. 2007;133(5):747–60.

    Article  PubMed  Google Scholar 

  21. Clarke TC, Black LI, Stussman BJ, Barnes PM, Nahin RL. Trends in the use of complementary health approaches among adults: United States, 2002–2012. Natl Health Stat Rep. 2015;79:1–16.

    Google Scholar 

  22. Simopoulos AP. Importance of the ratio of omega-6/omega-3 essential fatty acids: evolutionary aspects. World Rev Nutr Diet. 2003;92:1–22.

    Article  CAS  PubMed  Google Scholar 

  23. Ubeda N, Achon M, Varela-Moreiras G. Omega 3 fatty acids in the elderly. Br J Nutr. 2012;107(Suppl 2):S137–51.

    Article  CAS  PubMed  Google Scholar 

  24. Kotwal S, Jun M, Sullivan D, Perkovic V, Neal B. Omega 3 Fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2012;5(6):808–18.

    Article  PubMed  Google Scholar 

  25. Lopez HL. Nutritional interventions to prevent and treat osteoarthritis. Part I: focus on fatty acids and macronutrients. PM & R: J Inj Funct Rehabil. 2012;4(5 Suppl):S145–54.

    Google Scholar 

  26. Su KP, Matsuoka Y, Pae CU. Omega-3 polyunsaturated fatty acids in prevention of mood and anxiety disorders. Clin Psychopharmacol Neurosci: Off Sci J Kor College Neuropsychopharmacol. 2015;13(2):129–37.

    Article  Google Scholar 

  27. Tanskanen A, Hibbeln JR, Tuomilehto J, Uutela A, Haukkala A, Viinamaki H, et al. Fish consumption and depressive symptoms in the general population in Finland. Psychiatric Ser (Washington, DC). 2001;52(4):529–31.

    Google Scholar 

  28. Noaghiul S, Hibbeln JR. Cross-national comparisons of seafood consumption and rates of bipolar disorders. Am J Psychiatry. 2003;160(12):2222–7.

    Article  PubMed  Google Scholar 

  29. Harris WS. The omega-3 index: clinical utility for therapeutic intervention. Curr Cardiol Rep. 2010;12(6):503–8.

    Article  PubMed  Google Scholar 

  30. McNamara RK, Jandacek R, Rider T, Tso P, Dwivedi Y, Pandey GN. Selective deficits in erythrocyte docosahexaenoic acid composition in adult patients with bipolar disorder and major depressive disorder. J Affect Disord. 2010;126(1–2):303–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, Sitasawad S, et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res. 2003;121(2):109–22.

    Article  CAS  PubMed  Google Scholar 

  32. McNamara RK, Jandacek R, Tso P, Blom TJ, Welge JA, Strawn JR, et al. First-episode bipolar disorder is associated with erythrocyte membrane docosahexaenoic acid deficits: Dissociation from clinical response to lithium or quetiapine. Psychiatry Res. 2015;230(2):447–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry. 2007;68(7):1056–61.

    Article  CAS  PubMed  Google Scholar 

  34. Williams AL, Katz D, Ali A, Girard C, Goodman J, Bell I. Do essential fatty acids have a role in the treatment of depression? J Affect Disord. 2006;93(1–3):117–23.

    Article  CAS  PubMed  Google Scholar 

  35. Su KP, Wang SM, Pae CU. Omega-3 polyunsaturated fatty acids for major depressive disorder. Expert Opin Investig Drugs. 2013;22(12):1519–34.

    Article  CAS  PubMed  Google Scholar 

  36. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1999;56(5):407–12.

    Article  CAS  PubMed  Google Scholar 

  37. Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry: J Ment Sci. 2006;188:46–50.

    Article  Google Scholar 

  38. Hirashima F, Parow AM, Stoll AL, Demopulos CM, Damico KE, Rohan ML, et al. Omega-3 fatty acid treatment and T(2) whole brain relaxation times in bipolar disorder. Am J Psychiatry. 2004;161(10):1922–4.

    Article  PubMed  Google Scholar 

  39. Keck PE Jr, Mintz J, McElroy SL, Freeman MP, Suppes T, Frye MA, et al. Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry. 2006;60(9):1020–2.

    Article  CAS  PubMed  Google Scholar 

  40. Chiu CC, Huang SY, Chen CC, Su KP. Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder. J Clin Psychiatry. 2005;66(12):1613–4.

    Article  PubMed  Google Scholar 

  41. Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry. 2012;73(1):81–6.

    Article  CAS  PubMed  Google Scholar 

  42. Eritsland J, Arnesen H, Gronseth K, Fjeld NB, Abdelnoor M. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol. 1996;77(1):31–6.

    Article  CAS  PubMed  Google Scholar 

  43. Papakostas GI. Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder. J Clin Psychiatry. 2009;70(Suppl 5):18–22.

    Article  CAS  PubMed  Google Scholar 

  44. Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr. 2002;76(5):1158s–61s.

    CAS  PubMed  Google Scholar 

  45. Murphy BL, Babb SM, Ravichandran C, Cohen BM. Oral SAMe in persistent treatment-refractory bipolar depression: a double-blind, randomized clinical trial. J Clin Psychopharmacol. 2014;34(3):413–6.

    Article  PubMed  Google Scholar 

  46. Carney MW, Chary TK, Bottiglieri T, Reynolds EH. The switch mechanism and the bipolar/unipolar dichotomy. Br J Psychiatry: J Ment Sci. 1989;154:48–51.

    Article  CAS  Google Scholar 

  47. Lipinski JF, Cohen BM, Frankenburg F, Tohen M, Waternaux C, Altesman R, et al. Open trial of S-adenosylmethionine for treatment of depression. Am J Psychiatry. 1984;141(3):448–50.

    Article  CAS  PubMed  Google Scholar 

  48. Steullet P, Cabungcal JH, Monin A, Dwir D, O’Donnell P, Cuenod M, et al. Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: a “central hub” in schizophrenia pathophysiology? Schizophr Res. 2016;176(1):41–51.

    Article  CAS  PubMed  Google Scholar 

  49. Tuncel OK, Sarisoy G, Bilgici B, Pazvantoglu O, Cetin E, Unverdi E, et al. Oxidative stress in bipolar and schizophrenia patients. Psychiatry Res. 2015;228(3):688–94.

    Article  PubMed  CAS  Google Scholar 

  50. Brown NC, Andreazza AC, Young LT. An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res. 2014;218(1–2):61–8.

    Article  CAS  PubMed  Google Scholar 

  51. Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder—a double-blind randomized placebo-controlled trial. Biol Psychiatry. 2008;64(6):468–75.

    Article  CAS  PubMed  Google Scholar 

  52. Dean OM, Bush AI, Copolov DL, Kohlmann K, Jeavons S, Schapkaitz I, et al. Effects of N-acetyl cysteine on cognitive function in bipolar disorder. Psychiatry Clin Neurosci. 2012;66(6):514–7.

    Article  CAS  PubMed  Google Scholar 

  53. Berk M, Dean OM, Cotton SM, Gama CS, Kapczinski F, Fernandes B, et al. Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial. BMC Med. 2012;10:91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Deepmala, Slattery J, Kumar N, Delhey L, Berk M, Dean O, et al. Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review. Neurosci Biobehav Rev. 2015;55:294–321.

    Google Scholar 

  55. McTavish SF, McPherson MH, Harmer CJ, Clark L, Sharp T, Goodwin GM, et al. Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness. Br J Psychiatry: J Ment Sci. 2001;179:356–60.

    Article  CAS  Google Scholar 

  56. Scarna A, Gijsman HJ, McTavish SF, Harmer CJ, Cowen PJ, Goodwin GM. Effects of a branched-chain amino acid drink in mania. Br J Psychiatry: J Ment Sci. 2003;182:210–3.

    Article  CAS  Google Scholar 

  57. Chengappa KN, Levine J, Gershon S, Mallinger AG, Hardan A, Vagnucci A, et al. Inositol as an add-on treatment for bipolar depression. Bipolar Disord. 2000;2(1):47–55.

    Article  CAS  PubMed  Google Scholar 

  58. Eden Evins A, Demopulos C, Yovel I, Culhane M, Ogutha J, Grandin LD, et al. Inositol augmentation of lithium or valproate for bipolar depression. Bipolar Disord. 2006;8(2):168–74.

    Article  CAS  PubMed  Google Scholar 

  59. Coppen A, Chaudhry S, Swade C. Folic acid enhances lithium prophylaxis. J Affect Disord. 1986;10(1):9–13.

    Article  CAS  PubMed  Google Scholar 

  60. Behzadi AH, Omrani Z, Chalian M, Asadi S, Ghadiri M. Folic acid efficacy as an alternative drug added to sodium valproate in the treatment of acute phase of mania in bipolar disorder: a double-blind randomized controlled trial. Acta Psychiatr Scand. 2009;120(6):441–5.

    Article  CAS  PubMed  Google Scholar 

  61. Clay HB, Sillivan S, Konradi C. Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int J Dev Neurosci: Off J Int Soc Dev Neurosci. 2011;29(3):311–24.

    Article  CAS  Google Scholar 

  62. Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry. 2005;10(10):900–19.

    Article  CAS  PubMed  Google Scholar 

  63. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35(3):804–17.

    Article  CAS  PubMed  Google Scholar 

  64. Moylan S, Berk M, Dean OM, Samuni Y, Williams LJ, O’Neil A, et al. Oxidative & nitrosative stress in depression: Why so much stress? Neurosci Biobehav Rev. 2014;45:46–62.

    Article  CAS  PubMed  Google Scholar 

  65. Morris G, Anderson G, Berk M, Maes M. Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implications. Mol Neurobiol. 2013;48(3):883–903.

    Article  CAS  PubMed  Google Scholar 

  66. Forester BP, Harper DG, Georgakas J, Ravichandran C, Madurai N, Cohen BM. Antidepressant effects of open label treatment with coenzyme Q10 in geriatric bipolar depression. J Clin Psychopharmacol. 2015;35(3):338–40.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Sarris J St. John’s wort for the treatment of psychiatric disorders. Psychiatric Clin N Am. 2013;36(1):65–72.

    Article  Google Scholar 

  68. Linde K, Mulrow CD, Berner M, Egger M. St John’s wort for depression. Cochrane Database Syst Rev. 2005(2):Cd000448.

    Google Scholar 

  69. Muller WE. Current St John’s wort research from mode of action to clinical efficacy. Pharmacol Res. 2003;47(2):101–9.

    Article  CAS  PubMed  Google Scholar 

  70. Harrer G, Schmidt U, Kuhn U, Biller A. Comparison of equivalence between the St. John’s wort extract LoHyp-57 and fluoxetine. Arzneimittelforschung. 1999;49(4):289–96.

    CAS  PubMed  Google Scholar 

  71. Solomon D, Adams J, Graves N. Economic evaluation of St. John’s wort (Hypericum perforatum) for the treatment of mild to moderate depression. J Affect Disord. 2013;148(2–3):228–34.

    Article  PubMed  Google Scholar 

  72. Kasper S, Gastpar M, Moller HJ, Muller WE, Volz HP, Dienel A, et al. Better tolerability of St. John’s wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression. Int Clin Psychopharmacol. 2010;25(4):204–13.

    Article  PubMed  Google Scholar 

  73. Moses EL, Mallinger AG. St. John’s Wort: three cases of possible mania induction. J Clin Psychopharmacol. 2000;20(1):115–7.

    Article  CAS  PubMed  Google Scholar 

  74. Fahmi M, Huang C, Schweitzer I. A case of mania induced by hypericum. World J Biol Psychiatry. 2002;3(1):58–9.

    Article  PubMed  Google Scholar 

  75. Madhusoodanan S, Velama U, Parmar J, Goia D, Brenner R. A current review of cytochrome P450 interactions of psychotropic drugs. Ann Clin Psychiatry. 2014;26(2):120–38.

    PubMed  Google Scholar 

  76. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John’s wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol. 2002;54(4):349–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Chiesa A, Serretti A. Mindfulness based cognitive therapy for psychiatric disorders: a systematic review and meta-analysis. Psychiatry Res. 2011;187(3):441–53.

    Article  PubMed  Google Scholar 

  78. Chiesa A, Serretti A. A systematic review of neurobiological and clinical features of mindfulness meditations. Psychol Med. 2010;40(8):1239–52.

    Article  CAS  PubMed  Google Scholar 

  79. Chiesa A, Serretti A. Mindfulness-based interventions for chronic pain: a systematic review of the evidence. J Altern Complement Med (New York, NY). 2011;17(1):83–93.

    Google Scholar 

  80. Chiesa A, Serretti A. Are mindfulness-based interventions effective for substance use disorders? A systematic review of the evidence. Subst Use Misuse. 2014;49(5):492–512.

    Article  PubMed  Google Scholar 

  81. Kabat-Zinn J. Wherever you go, there you are: mindfulness meditation in everyday life. New York: Hyperion; 2005. xxi, 280 p.

    Google Scholar 

  82. Kabat-Zinn J, Massion AO, Kristeller J, Peterson LG, Fletcher KE, Pbert L, et al. Effectiveness of a meditation-based stress reduction program in the treatment of anxiety disorders. Am J Psychiatry. 1992;149(7):936–43.

    Article  CAS  PubMed  Google Scholar 

  83. Kabat-Zinn J. An outpatient program in behavioral medicine for chronic pain patients based on the practice of mindfulness meditation: theoretical considerations and preliminary results. Gen Hosp Psychiatry. 1982;4(1):33–47.

    Article  CAS  PubMed  Google Scholar 

  84. Ma SH, Teasdale JD. Mindfulness-based cognitive therapy for depression: replication and exploration of differential relapse prevention effects. J Consult Clin Psychol. 2004;72(1):31–40.

    Article  PubMed  Google Scholar 

  85. Teasdale JD, Segal ZV, Williams JM, Ridgeway VA, Soulsby JM, Lau MA. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. J Consult Clin Psychol. 2000;68(4):615–23.

    Article  CAS  PubMed  Google Scholar 

  86. Deckersbach T, Holzel BK, Eisner LR, Stange JP, Peckham AD, Dougherty DD, et al. Mindfulness-based cognitive therapy for nonremitted patients with bipolar disorder. CNS Neurosci Ther. 2012;18(2):133–41.

    Article  PubMed  Google Scholar 

  87. Williams JM, Alatiq Y, Crane C, Barnhofer T, Fennell MJ, Duggan DS, et al. Mindfulness-based Cognitive Therapy (MBCT) in bipolar disorder: preliminary evaluation of immediate effects on between-episode functioning. J Affect Disord. 2008;107(1–3):275–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Perich T, Manicavasagar V, Mitchell PB, Ball JR, Hadzi-Pavlovic D. A randomized controlled trial of mindfulness-based cognitive therapy for bipolar disorder. Acta Psychiatr Scand. 2013;127(5):333–43.

    Article  CAS  PubMed  Google Scholar 

  89. Segal ZV, Williams JMG, Teasdale JD. Mindfulness-based cognitive therapy for depression. 2nd ed. New York: Guilford Press; 2013. xix, 451 p.

    Google Scholar 

  90. Kuyken W, Byford S, Taylor RS, Watkins E, Holden E, White K, et al. Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. J Consult Clin Psychol. 2008;76(6):966–78.

    Article  PubMed  Google Scholar 

  91. Eisendrath SJ, Gillung E, Delucchi K, Mathalon DH, Yang TT, Satre DD, et al. A preliminary study: efficacy of mindfulness-based cognitive therapy versus sertraline as first-line treatments for major depressive disorder. Mindfulness. 2015;6(3):475–82.

    Article  PubMed  Google Scholar 

  92. Stange JP, Eisner LR, Holzel BK, Peckham AD, Dougherty DD, Rauch SL, et al. Mindfulness-based cognitive therapy for bipolar disorder: effects on cognitive functioning. J Psychiatr Pract. 2011;17(6):410–9.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Lahera G, Bayon C, Fe Bravo-Ortiz M, Rodriguez-Vega B, Barbeito S, Saenz M, et al. Mindfulness-based cognitive therapy versus psychoeducational intervention in bipolar outpatients with sub-threshold depressive symptoms: a randomized controlled trial. BMC Psychiatry. 2014;14:215.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Townsend J, Bookheimer SY, Foland-Ross LC, Sugar CA, Altshuler LL. fMRI abnormalities in dorsolateral prefrontal cortex during a working memory task in manic, euthymic and depressed bipolar subjects. Psychiatry Res. 2010;182(1):22–9.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Burdick KE, Russo M, Frangou S, Mahon K, Braga RJ, Shanahan M, et al. Empirical evidence for discrete neurocognitive subgroups in bipolar disorder: clinical implications. Psychol Med. 2014;44(14):3083–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Malhi GS, Ivanovski B, Hadzi-Pavlovic D, Mitchell PB, Vieta E, Sachdev P. Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia. Bipolar Disord. 2007;9(1–2):114–25.

    Article  PubMed  Google Scholar 

  97. Robinson LJ, Ferrier IN. Evolution of cognitive impairment in bipolar disorder: a systematic review of cross-sectional evidence. Bipolar Disord. 2006;8(2):103–16.

    Article  PubMed  Google Scholar 

  98. Howells FM, Ives-Deliperi VL, Horn NR, Stein DJ. Mindfulness based cognitive therapy improves frontal control in bipolar disorder: a pilot EEG study. BMC Psychiatry. 2012;12:15.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Ives-Deliperi VL, Howells F, Stein DJ, Meintjes EM, Horn N. The effects of mindfulness-based cognitive therapy in patients with bipolar disorder: a controlled functional MRI investigation. J Affect Disord. 2013;150(3):1152–7.

    Article  PubMed  Google Scholar 

  100. Howells FM, Laurie Rauch HG, Ives-Deliperi VL, Horn NR, Stein DJ. Mindfulness based cognitive therapy may improve emotional processing in bipolar disorder: pilot ERP and HRV study. Metab Brain Dis. 2014;29(2):367–75.

    Article  PubMed  Google Scholar 

  101. Lopresti AL, Jacka FN. Diet and bipolar disorder: a review of its relationship and potential therapeutic mechanisms of action. J Altern Complement Med. 2015;21(12):733–9.

    Article  PubMed  Google Scholar 

  102. Thomson D, Turner A, Lauder S, Gigler ME, Berk L, Singh AB, et al. A brief review of exercise, bipolar disorder, and mechanistic pathways. Front Psychol. 2015;6:147.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Sylvia LG, Ametrano RM, Nierenberg AA. Exercise treatment for bipolar disorder: potential mechanisms of action mediated through increased neurogenesis and decreased allostatic load. Psychother Psychosom. 2010;79(2):87–96.

    Article  PubMed  Google Scholar 

  104. Fernandes BS, Berk M, Turck CW, Steiner J, Goncalves CA. Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis. Mol Psychiatry. 2014;19(7):750–1.

    Article  CAS  PubMed  Google Scholar 

  105. Fernandes BS, Gama CS, Cereser KM, Yatham LN, Fries GR, Colpo G, et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res. 2011;45(8):995–1004.

    Article  PubMed  Google Scholar 

  106. de Sa Filho AS, de Souza Moura AM, Lamego MK, Rocha NB, Paes F, Oliveira AC, et al. Potential therapeutic effects of physical exercise for Bipolar Disorder. CNS Neurol Disord: Drug Targets. 2015;14(10):1255–9.

    Article  CAS  Google Scholar 

  107. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry. 2009;70(8):1078–90.

    Article  PubMed  Google Scholar 

  108. Hamer M, Steptoe A. Association between physical fitness, parasympathetic control, and proinflammatory responses to mental stress. Psychosom Med. 2007;69(7):660–6.

    Article  PubMed  Google Scholar 

  109. Melo MC, Daher Ede F, Albuquerque SG, de Bruin VM. Exercise in bipolar patients: a systematic review. J Affect Disord. 2016;198:32–8.

    Article  PubMed  Google Scholar 

  110. Ng F, Dodd S, Berk M. The effects of physical activity in the acute treatment of bipolar disorder: a pilot study. J Affect Disord. 2007;101(1–3):259–62.

    Article  PubMed  Google Scholar 

  111. Knubben K, Reischies FM, Adli M, Schlattmann P, Bauer M, Dimeo F. A randomised, controlled study on the effects of a short-term endurance training programme in patients with major depression. Br J Sports Med. 2007;41(1):29–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Sylvia LG, Salcedo S, Bernstein EE, Baek JH, Nierenberg AA, Deckersbach T. Nutrition, exercise, and wellness treatment in bipolar disorder: proof of concept for a consolidated intervention. Int J Bipolar Disorders. 2013;1(1):24.

    Article  Google Scholar 

  113. Van Citters AD, Pratt SI, Jue K, Williams G, Miller PT, Xie H, et al. A pilot evaluation of the In SHAPE individualized health promotion intervention for adults with mental illness. Commun Ment Health J. 2010;46(6):540–52.

    Article  Google Scholar 

  114. Wright K, Armstrong T, Taylor A, Dean S. ‘It’s a double edged sword’: a qualitative analysis of the experiences of exercise amongst people with Bipolar Disorder. J Affect Disord. 2012;136(3):634–42.

    Article  PubMed  Google Scholar 

  115. Crump C, Sundquist K, Winkleby MA, Sundquist J. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry. 2013;70(9):931–9.

    Article  PubMed  Google Scholar 

  116. Morriss R, Mohammed FA. Metabolism, lifestyle and bipolar affective disorder. J Psychopharmacol (Oxford, England). 2005;19(6 Suppl):94–101.

    Google Scholar 

  117. da Silva TL, Ravindran LN, Ravindran AV. Yoga in the treatment of mood and anxiety disorders: a review. Asian J Psychiatr. 2009;2(1):6–16.

    Article  PubMed  Google Scholar 

  118. Streeter CC, Gerbarg PL, Saper RB, Ciraulo DA, Brown RP. Effects of yoga on the autonomic nervous system, gamma-aminobutyric-acid, and allostasis in epilepsy, depression, and post-traumatic stress disorder. Med Hypotheses. 2012;78(5):571–9.

    Article  CAS  PubMed  Google Scholar 

  119. Brown RP, Gerbarg PL. Sudarshan Kriya Yogic breathing in the treatment of stress, anxiety, and depression. Part II–clinical applications and guidelines. J Altern Complement Med (New York, NY). 2005;11(4):711–7.

    Google Scholar 

  120. Uebelacker LA, Weinstock LM, Kraines MA. Self-reported benefits and risks of yoga in individuals with bipolar disorder. J Psychiatr Pract. 2014;20(5):345–52.

    Article  PubMed  Google Scholar 

  121. Abreu T, Braganca M. The bipolarity of light and dark: a review on bipolar disorder and circadian cycles. J Affect Disord. 2015;185:219–29.

    Article  CAS  PubMed  Google Scholar 

  122. Salvatore P, Ghidini S, Zita G, De Panfilis C, Lambertino S, Maggini C, et al. Circadian activity rhythm abnormalities in ill and recovered bipolar I disorder patients. Bipolar Disord. 2008;10(2):256–65.

    Article  PubMed  Google Scholar 

  123. Benedetti F, Colombo C, Pontiggia A, Bernasconi A, Florita M, Smeraldi E. Morning light treatment hastens the antidepressant effect of citalopram: a placebo-controlled trial. J Clin Psychiatry. 2003;64(6):648–53.

    Article  CAS  PubMed  Google Scholar 

  124. Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP. Light suppresses melatonin secretion in humans. Science (New York, NY). 1980;210(4475):1267–9.

    Article  CAS  Google Scholar 

  125. Wu JC, Kelsoe JR, Schachat C, Bunney BG, DeModena A, Golshan S, et al. Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder. Biol Psychiatry. 2009;66(3):298–301.

    Article  CAS  PubMed  Google Scholar 

  126. Tseng PT, Chen YW, Tu KY, Chung W, Wang HY, Wu CK, et al. Light therapy in the treatment of patients with bipolar depression: a meta-analytic study. Eur Neuropsychopharmacol: J Eur College Neuropsychopharmacol. 2016;26(6):1037–47.

    Article  CAS  Google Scholar 

  127. Sit D, Wisner KL, Hanusa BH, Stull S, Terman M. Light therapy for bipolar disorder: a case series in women. Bipolar Disord. 2007;9(8):918–27.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 12 Executive Park Drive NE, Suite 331, Atlanta, GA, 30329, USA

    Maria Cristina Poscablo-Stein & Adriana P. Hermida

Authors
  1. Maria Cristina Poscablo-Stein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adriana P. Hermida
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adriana P. Hermida .

Editor information

Editors and Affiliations

  1. School of Medicine, The Johns Hopkins University School of Medicine, BALTIMORE, Maryland, USA

    Susan W. Lehmann

  2. Department of Psychiatry, McLean Hospital Harvard Medical School, Belmont, Massachusetts, USA

    Brent P. Forester

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Poscablo-Stein, M.C., Hermida, A.P. (2017). Complementary and Integrative Therapies for Older Age Bipolar Disorder. In: Lehmann, S., Forester, B. (eds) Bipolar Disorder in Older Age Patients. Springer, Cham. https://doi.org/10.1007/978-3-319-48912-4_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-48912-4_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-48910-0

  • Online ISBN: 978-3-319-48912-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation